This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2017-2019.
Company Filing History:
Years Active: 2017-2019
Title: Alexander Kirschner: Innovator in Psychiatric Disorder Treatments
Introduction
Alexander Kirschner is a notable inventor based in Munich, Germany. He has made significant contributions to the field of psychiatric disorder treatments, holding a total of 2 patents. His work focuses on developing selective FKBP51 ligands that can be used for the treatment and prophylaxis of psychiatric disorders and neurodegenerative diseases.
Latest Patents
Kirschner's latest patents include innovative compounds that feature a selective FKBP51 ligand scaffold. These compounds are designed to be used in pharmaceutical compositions, which include pharmaceutically acceptable salts, carriers, excipients, and diluents. The applications of these selective FKBP51 ligand compounds are aimed at addressing psychiatric disorders and neurodegenerative diseases, providing new avenues for treatment.
Career Highlights
Throughout his career, Alexander Kirschner has worked with prestigious institutions such as the Max Planck Society for the Advancement of Science and Technische Universität Darmstadt. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Steffen Gaali and Felix Hausch. Their collaborative efforts have further advanced the research and development of treatments for psychiatric disorders.
Conclusion
Alexander Kirschner's innovative work in the field of psychiatric disorder treatments highlights his commitment to improving mental health through scientific advancements. His contributions are paving the way for new therapeutic options in the medical community.